menu search

BIOC / Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue

Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
Biocept, Inc. has reported a strong rise in full-year 2021 revenue due to growth in volumes for reverse transcription (RT) PCR coronavirus (COVID-19) testing.  The company, a leading provider of molecular diagnostic assays, products and services, said net revenues for the year to December 31, 2021, reached $61.2 million, a 123% increase from $27.5 million in 2020. Read More
Posted: Apr 6 2022, 11:37
Author Name: Proactive Investors
Views: 110935

BIOC News  

Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)

By Seeking Alpha
August 30, 2023

Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)

Biocept, Inc. (NASDAQ:BIOC ) Business Update Conference Call August 30, 2023 4:00 PM ET Company Participants Jody Cain - LHA Antonino Morales - Presid more_horizontal

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

By InvestorPlace
August 25, 2023

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product. more_horizontal

Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference

By Proactive Investors
August 14, 2023

Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference

Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology more_horizontal

Biocept appoints Antonino Morales as president and chief executive officer

By Proactive Investors
June 21, 2023

Biocept appoints Antonino Morales as president and chief executive officer

Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately. Mora more_horizontal

Why Is Biocept (BIOC) Stock Down 42% Today?

By InvestorPlace
May 25, 2023

Why Is Biocept (BIOC) Stock Down 42% Today?

Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering more_horizontal

Biocept shares to commence trading on split-adjusted basis

By Proactive Investors
May 17, 2023

Biocept shares to commence trading on split-adjusted basis

Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock w more_horizontal

Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year

By Proactive Investors
April 17, 2023

Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year

Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay more_horizontal

Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases

By Proactive Investors
March 24, 2023

Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases

Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metas more_horizontal


Search within

Pages Search Results: